Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The size of myocardial infarction and peri-infarction edema are not major determinants of diastolic impairment after acute myocardial infarction.
Sundqvist MG, Verouhis D, Sörensson P, Henareh L, Persson J, Saleh N, Settergren M, Witt N, Böhm F, Pernow J, Tornvall P, Ugander M. Sundqvist MG, et al. Among authors: witt n. Int J Cardiovasc Imaging. 2024 Dec 5. doi: 10.1007/s10554-024-03294-6. Online ahead of print. Int J Cardiovasc Imaging. 2024. PMID: 39636337
Impact of a Chronic Total Occlusion on Outcomes After FFR-Guided PCI or Coronary Bypass Surgery: A FAME 3 Substudy.
Otsuki H, Takahashi K, Zimmermann FM, Mavromatis K, Aminian A, Jagic N, Dambrink JE, Kala P, MacCarthy P, Witt N, Kobayashi Y, Takahashi T, Woo YJ, Yeung AC, De Bruyne B, Pijls NHJ, Fearon WF; FAME 3 Trial Investigators. Otsuki H, et al. Among authors: witt n. Circ Cardiovasc Interv. 2024 Nov;17(11):e014300. doi: 10.1161/CIRCINTERVENTIONS.124.014300. Epub 2024 Nov 6. Circ Cardiovasc Interv. 2024. PMID: 39502029 Clinical Trial.
Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study.
Ray KK, Aguiar C, Arca M, Connolly DL, Eriksson M, Ferrières J, Laufs U, Mostaza JM, Nanchen D, Bardet A, Lamparter M, Chhabra R, Soronen J, Rietzschel E, Strandberg T, Toplak H, Visseren FLJ, Catapano AL; SANTORINI Study Investigators. Ray KK, et al. Eur J Prev Cardiol. 2024 Nov 11;31(15):1792-1803. doi: 10.1093/eurjpc/zwae199. Eur J Prev Cardiol. 2024. PMID: 38861400
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG; ODYSSEY OUTCOMES Investigators. Goodman SG, et al. Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):342-352. doi: 10.1093/ehjcvp/pvae025. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38658193 Free PMC article. Review.
FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
Böhm F, Mogensen B, Engstrøm T, Stankovic G, Srdanovic I, Lønborg J, Zwackman S, Hamid M, Kellerth T, Lauermann J, Kajander OA, Andersson J, Linder R, Angerås O, Renlund H, Ērglis A, Menon M, Schultz C, Laine M, Held C, Rück A, Östlund O, James S; FULL REVASC Trial Investigators. Böhm F, et al. N Engl J Med. 2024 Apr 25;390(16):1481-1492. doi: 10.1056/NEJMoa2314149. Epub 2024 Apr 8. N Engl J Med. 2024. PMID: 38587995 Clinical Trial.
153 results